Stem Cell-Derived Blood Products for Therapeutic Use: Technology Improvement (R43/R44)

Funding Agency:
National Institutes of Health
The primary objective of this funding opportunity announcement is to support the development of improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner. The research supported will develop and enhance technologies that enable the production of functional stem cell-based therapies with potential commercial and clinical viability.
 
Companion FOAs:
RFA-HL-15-022 supports R01 grants to address the basic or early translational research needs whereas this Small Business Innovation Research (SBIR) Phase I and Phase II (R43/44) FOA along with the companion Small Business Technology Transfer Research (STTR) Phase I (R41) FOA (RFA-HL-15-029 ) supports small business awards to enable further advances in the manufacturing processes.
 
Deadlines:
  • Letter of Intent Due Date(s): 30 days prior to the application due date

  • Application Due Date(s): February 20, 2015 (Phase I or Fast-Track); February 20, 2016 (Phase I; Phase II; or Fast-Track); February 20, 2017 (Phase II only)

RFA-HL-15-030 Expiration Date New Date July 21, 2017 per issuance of NOT-HL-16-464. (Original Expiration Date: February 21, 2017)

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Funding Type

Grant

Eligibility

Faculty

Category

Engineering and Physical Sciences
Medical
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

February 20, 2017